The role of S1P on lymphocyte migration and egress from lymphoid organs has been extensively studied and resulted in the development of the S1PR1 functional agonist fingolimod for the treatment of autoimmune diseases such as MS (140). This evidence concerns the gene S1PR1 and myeloid sarcoma.